Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy

Launched by MOHSEN POURAZIZI · Jan 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether taking melatonin, a natural sleep aid, can help improve vision and reduce swelling in the central part of the retina (the macula) in adults with a condition called central serous chorioretinopathy (CSCR). Researchers want to find out if melatonin can make a difference compared to a placebo, which is a pill that looks like the medication but has no active ingredients. Participants in the trial will take either melatonin or the placebo twice a day for a month and will visit the clinic after their treatment, as well as one and three months later, to check their vision and track any symptoms in a diary.

To be eligible for this trial, participants need to be at least 18 years old and have a recent diagnosis of CSCR confirmed by doctors. However, individuals with certain eye conditions or recent eye surgeries, as well as pregnant or nursing women, will not be able to participate. This study aims to provide valuable information about the potential benefits of melatonin for those affected by CSCR, and it's important to note that the trial is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks
• • 2. Patients with minimum age of 18 years old
• • 3. Consent to participate in the study
• Exclusion Criteria:
• • 1. A history of vitrectomy
• • 2. A history of laser surgery in the eye being studied in the past 3 months
• • 3. A history of anti-VEGF injection in the eye being studied in the past 3 months
• • 4. History of patient suspicious for choroidal neovascularization (CNV)
• • 5. Pregnant or nursing patients
• • 6. Patients with significantly compromised visual acuity in the eye being studied due to concomitant ocular condition
• • 7. Patients participating in any other investigational drug study
• • 8. Inability to obtain OCT photographs